Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06323213
PHASE3
Efficacy and Safety Study of 610 in Patients With Severe Asthma
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
480
Start Date
2024-06-24
Completion Date
2027-09
Last Updated
2026-01-07
Healthy Volunteers
No
Conditions
Interventions
DRUG
610
610 subcutaneously injection.
DRUG
Placebo
Placebo subcutaneously injection.
Locations (1)
Shanghai General Hospital
Shanghai, Shanghai Municipality, China